CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

CheckMate 77T Trial Results Support Nivolumab for Resectable NSCLC

NSCLC 围术期治疗：BMS 公布CheckMate-77T 临床结果

Neoadjuvant therapy in non-small cell lung cancer - ScienceDirect

New data support perioperative nivolumab for NSCLC

MD Anderson Research Highlights: ESMO 2023 Special Edition

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab

PharmaScroll on LinkedIn: Phase 3 Trial Shows Neoadjuvant

Neoadjuvant immunotherapy/target therapy trials.

News from ESMO - Lung Cancer Research Foundation

Pre- and Postsurgical Immunotherapy Improves Outcomes in Operable

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

The earlier, the better? A review of neoadjuvant immunotherapy in

Adding Adjuvant Nivolumab Builds on Standard of Care for